Michael Cherny
Stock Analyst at Leerink Partners
(3.69)
# 781
Out of 4,981 analysts
116
Total ratings
52.87%
Success rate
7.02%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PINC Premier | Maintains: Underperform | $19 → $21 | $26.43 | -20.54% | 10 | Aug 19, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $188 → $186 | $151.38 | +22.87% | 13 | Aug 12, 2025 | |
| PGNY Progyny | Upgrades: Outperform | $28 | $22.53 | +24.28% | 11 | Jul 8, 2025 | |
| BOLD Boundless Bio | Downgrades: Market Perform | $15 → $3 | $1.16 | +158.62% | 2 | May 28, 2025 | |
| MCK McKesson | Maintains: Buy | $755 → $800 | $708.00 | +12.99% | 13 | May 9, 2025 | |
| NVST Envista Holdings | Maintains: Buy | $26 → $23 | $20.99 | +9.58% | 11 | Apr 29, 2025 | |
| MEDP Medpace Holdings | Initiates: Market Perform | $330 | $489.50 | -32.58% | 1 | Mar 24, 2025 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $24 → $40 | $55.24 | -27.59% | 10 | Feb 25, 2025 | |
| CVS CVS Health | Upgrades: Outperform | $55 → $75 | $73.03 | +2.70% | 11 | Feb 13, 2025 | |
| DOCS Doximity | Upgrades: Outperform | $60 → $90 | $72.64 | +23.90% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $235 → $280 | $131.59 | +112.78% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $135 → $174 | $181.10 | -3.92% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $69 → $84 | $68.53 | +22.58% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $187.23 | +32.46% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $171.48 | +48.71% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $13.54 | - | 8 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $296.95 | -7.39% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $275.20 | -5.52% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $4.17 | +92.08% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $19 | $11.25 | +68.89% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $17 | $7.71 | +120.64% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $4.80 | +993.75% | 2 | Jan 5, 2022 |
Premier
Aug 19, 2025
Maintains: Underperform
Price Target: $19 → $21
Current: $26.43
Upside: -20.54%
Cardinal Health
Aug 12, 2025
Maintains: Outperform
Price Target: $188 → $186
Current: $151.38
Upside: +22.87%
Progyny
Jul 8, 2025
Upgrades: Outperform
Price Target: $28
Current: $22.53
Upside: +24.28%
Boundless Bio
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.16
Upside: +158.62%
McKesson
May 9, 2025
Maintains: Buy
Price Target: $755 → $800
Current: $708.00
Upside: +12.99%
Envista Holdings
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $20.99
Upside: +9.58%
Medpace Holdings
Mar 24, 2025
Initiates: Market Perform
Price Target: $330
Current: $489.50
Upside: -32.58%
Hims & Hers Health
Feb 25, 2025
Maintains: Market Perform
Price Target: $24 → $40
Current: $55.24
Upside: -27.59%
CVS Health
Feb 13, 2025
Upgrades: Outperform
Price Target: $55 → $75
Current: $73.03
Upside: +2.70%
Doximity
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $72.64
Upside: +23.90%
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $131.59
Upside: +112.78%
Jan 6, 2025
Upgrades: Outperform
Price Target: $135 → $174
Current: $181.10
Upside: -3.92%
Jan 6, 2025
Upgrades: Buy
Price Target: $69 → $84
Current: $68.53
Upside: +22.58%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $187.23
Upside: +32.46%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $171.48
Upside: +48.71%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $13.54
Upside: -
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $296.95
Upside: -7.39%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $275.20
Upside: -5.52%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $4.17
Upside: +92.08%
Feb 26, 2024
Initiates: Market Perform
Price Target: $19
Current: $11.25
Upside: +68.89%
Feb 26, 2024
Initiates: Market Perform
Price Target: $17
Current: $7.71
Upside: +120.64%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $4.80
Upside: +993.75%